PRO-131921

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePRO-131921
Drug Alias NamePRO 131921PRO-131921
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunosuppressantsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A